Oxford BioMedica plc (LON:OXB) was upgraded by investment analysts at N+1 Singer to a “hold” rating in a research note issued on Friday.

Shares of Oxford BioMedica plc (LON:OXB) opened at 3.1053 on Friday. The company’s 50-day moving average price is GBX 3.63 and its 200-day moving average price is GBX 4.63. The company’s market cap is GBX 82.75 million. Oxford BioMedica plc has a 12 month low of GBX 2.98 and a 12 month high of GBX 8.45.

In other Oxford BioMedica plc news, insider Tallarigo ,Lorenzo bought 62,257 shares of Oxford BioMedica plc stock in a transaction on Thursday, August 25th. The shares were bought at an average price of GBX 4 ($0.05) per share, for a total transaction of £2,490.28 ($3,082.03). Also, insider Lorenzo Tallarigo bought 79,988 shares of Oxford BioMedica plc stock in a transaction on Monday, September 26th. The stock was acquired at an average price of GBX 3 ($0.04) per share, for a total transaction of £2,399.64 ($2,969.85).

Oxford BioMedica plc Company Profile

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Stock Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related stocks with our FREE daily email newsletter.